Bax W A, Saxena P R
Department of Pharmacology, Cardiovascular Research Institute COEUR, Faculty of Medicine and Health Sciences, Eramus University Rotterdam, The Netherlands.
Trends Pharmacol Sci. 1994 Oct;15(10):379-86. doi: 10.1016/0165-6147(94)90159-7.
The possible involvement of endothelins in a variety of diseases has attracted the attention of many pharmacologists in search of a novel therapeutic approach. The rapid development of endothelin research has resulted in the molecular characterization and pharmacological recognition of ETA and ETB receptors, and in the development of compounds selective for these receptors. However, the characterization of receptors in various assays has shown that a number of effects are mediated by receptors that do not fit the present criteria for ETA or ETB receptors. In this article, Willem Bax and Pramod Saxena address endothelin receptors in general, and atypical receptors in particular.
内皮素可能参与多种疾病，这吸引了许多药理学家的关注，他们致力于寻找新的治疗方法。内皮素研究的迅速发展，促成了ETA和ETB受体的分子特性鉴定和药理学识别，以及针对这些受体的选择性化合物的开发。然而，各种实验中的受体特性鉴定表明，许多效应是由不符合目前ETA或ETB受体标准的受体介导的。在本文中，威廉·巴克斯和普拉莫德·萨克森纳探讨了一般意义上的内皮素受体，特别是非典型受体。
